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Abstract
Purpose: This study aimed to develop a quality control framework for intensity modulated radiation therapy plan evaluations that can
account for variations in patient- and treatment-specific risk factors.
Methods and Materials: Patient-specific risk factors, such as a patient’s anatomy and tumor dose requirements, affect organs-at-risk
(OARs) dose-volume histograms (DVHs), which in turn affects plan quality and can potentially cause adverse effects. Treatment-
specific risk factors, such as the use of chemotherapy and surgery, are clinically relevant when evaluating radiation therapy planning
criteria. A risk-adjusted control chart was developed to identify unusual plan quality after accounting for patient- and treatment-
specific risk factors. In this proof of concept, 6 OAR DVH points and average monitor units serve as proxies for plan quality.
Eighteen risk factors are considered for modeling quality: planning target volume (PTV) and OAR cross-sectional areas; volumes,
spreads, and surface areas; minimum and centroid distances between OARs and the PTV; 6 PTV DVH points; use of
chemotherapy; and surgery. A total of 69 head and neck cases were used to demonstrate the application of risk-adjusted control
charts, and the results were compared with the application of conventional control charts.
Results: The risk-adjusted control chart remains robust to interpatient variations in the studied risk factors, unlike the conventional
control chart. For the brainstem, the conventional chart signaled 4 patients with unusual (out-of-control) doses to 2% brainstem volume.
However, the adjusted chart did not signal any plans after accounting for their risk factors. For the spinal cord doses to 2% brainstem
volume, the conventional chart signaled 2 patients, and the adjusted chart signaled a separate patient after accounting for their risk
factors. Similar adjustments were observed for the other DVH points when evaluating brainstem, spinal cord, ipsilateral parotid, and
average monitor units. The adjustments can be directly attributed to the patient- and treatment-specific risk factors.
Conclusions: A risk-adjusted control chart was developed to evaluate plan quality, which is robust to variations in patient- and
treatment-specific parameters.
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Introduction
Typically, treatment plan evaluation in intensity
modulated radiation therapy (IMRT) is performed by
comparing the patient’s dose distribution and volume
coverage to established thresholds. Often, the thresholds
need to be relaxed owing to patient- and treatment-
specific risk factors, such as the complexity of a pa-
tient’s anatomy, tumor dose requirements, use of
chemotherapy, or surgery. This process involves subjec-
tive decisions, leading to large variations in IMRT plan-
ning criteria across patients and making the planning
process irreproducible and plan quality incomparable
among patients.1
Quality control of the treatment planning process can
be captured using a control chart framework, as discussed
by Chung et al2 and Pawlicki et al.3,4 Most commonly,
control charts have been used in quality assurance of
dosimetry from the treatment planning system (TPS).
Individual, moving-range, standard deviation (SD), and
exponentially weighted moving average (EWMA) charts
were used to detect unusual trends in dose deviations
between the TPS and delivered dose.5,6 Alternatively,
Nordström et al7 found control charts to be effective for
the continuous verification of monitor units and derived
control limits that agree with international guidelines.
However, the use of control charts for treatment plan
evaluation has been limited due to planning process
variability for each patient, including patient- and
treatment-specific risk factors.
Alternatively, plan evaluations based on patient anat-
omy have been explored under the knowledge-based
planning (KBP) framework. Regression and machine-
learning models were used to predict organ-at-risk (OAR)
dose based on structure volumes, the planning target
volume (PTV) and OAR volume overlap, distance-to-
target histograms (DTH), and minimum distance between
OAR and PTV.8-10 In addition, a principal component
analysis was used to correlate OAR sparing to anatomic
features, such as the median distance between OAR and
PTV, portion of OAR volume within an specific distance,
OAR and PTV overlap, portion of OAR volume outside
the primary treatment field, and DTH.11,12 Additionally,
overlap volume histograms (OVHs) have been used to
capture the spatial configuration of an OAR with respect
to a target and suggest possible improvements in OAR
dose-volume histograms (DVHs), which were confirmed
by replanning.13 For further examples of plan evaluation
under the KBP framework, refer to Ge and Wu.14
In practice, RapidPlan provides a KBP implementation
to predict DVHs with upper and lower bounds at 1SD.15
These bounds account for some routine planning process
variability, but using 1SD under normally distributed
data substantially increases the probability of a false alarm
(type-I error) compared with using 3SD, as typically
used in control chart methodologies.16 In other words,
using 1SD leads to many more false-positives, which
require unnecessary reviews and clinical resources.
Furthermore, KBP cannot identify trends in planning
criteria because time is not considered. To address these
limitations, we propose merging modeling techniques
from KBP with control charts using 3SD limits and
plotting plans in chronological order.
In this proof of concept, we developed a risk-adjusted
control chart that can monitor plan quality after ac-
counting for patient- and treatment-specific risk factors.
The proposed control chart employs a risk-adjustment
model and a variety of risk factors that are discussed in
the following. In addition, we provide details of the pa-
tient set used for demonstration. Finally, the risk-adjusted
control chart is demonstrated in comparison with con-
ventional control charts.
Methods and Materials
Risk-adjusted control charts were developed for 6
OAR DVH points and average monitor units that serve as
proxies for plan quality. The 6 DVH points used are D2,
D20, D40, D60, D80, and D98, where Dx represents the
amount of the dose delivered to x% of the structure vol-
ume. Alternatively, the dose to the absolute volume can
be used in this framework. Average monitor units were
computed by dividing the total number of monitor units
by the number of beams in the plans. To develop the risk-
adjusted control charts, we first modeled plan quality
using the patient- and treatment-specific risk factors.
Then, we used the residuals from the risk adjustment
model to develop the risk-adjusted charts.
Risk adjustment model
Patient-specific risk factors, such as complex anatomic
geometry or high-dose prescriptions, can have an impact
on OAR Dx or monitor units.
7-12 Treatment-specific risk
factors, such as concurrent chemotherapy or surgery, are
clinically relevant when evaluating planning criteria. We
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model for the effect of such risk factors on OAR Dx, i for




bjzi;j þ εx;i; ð1Þ
where b0 is the intercept, bj is the coefficient associated
with the jth risk factor zi, j, and residuals ε are assumed to
follow a normal distribution N(0,s2) with constant vari-
ance. To achieve the best fit model, backward elimination
was employed for variable selection. For patient i, the
residual εx,iZDx,ibD x,i is the difference between the
observed Dx,i (which ignores the risk factors) and the
predicted bD x,i (which accounts for the risk factors).
Therefore, the residual εx,i represents an adjusted Dx,i that
effectively is free from the influence of risk factors zi,j
Then, the residuals are used within a control chart
framework to evaluate and monitor plan quality. Simi-
larly, a risk adjustment model is developed for average
monitor units, and the residuals are computed based on
the predicted and actual monitor units.
Risk-adjusted control chart
Conventional quality control charts plot the observa-
tions, in this case OAR Dx or average monitor units.
Residuals can be used as the plotting statistic if obser-
vations change depending on risk factors, and by plotting
residuals that are statistically independent of risk factors
and plan quality proxy, the effect of the risk factors is
removed.17
Individual control charts can be used to evaluate and
monitor individual observations, such as patient i’s re-
sidual εx,i (Eq. 1). The residual chart (hereinafter the risk-
adjusted control chart) consists of a center line (CL)
estimated as the mean of the residuals, εx; and lower and
upper control limits (LCL and UCL). The control limits
are 3SD from the CL, yielding a very low probability of
misclassifying a typical plan as unusual. The SD is esti-
mated using the average moving range MR of all
consecutive residual pairs, where the moving range for
patient i, MRiZ|εx,iþ1 εx,i| is the absolute difference in
residuals between patients i and iþ1. MR is standardized
by the constant d2Z1.128 to estimate SD (Eqs. 2 and 3).
The constant d2 is based on the number of consecutive
points used in the MRi computation (ie, 2 in this study, εx,i
and εx,iþ1).
18 Therefore, the LCL and UCL are
LCLZ εx  3MRd2 ; ð2Þ
and
UCLZ εx þ 3MRd2 : ð3Þ
The risk-adjusted control chart can identify residuals
outside of the control limits (ie, out-of-control [OC]). This
indicates an unusual plan quality, signaling the need for
further review because the unusual observation likely
cannot be attributed to the risk factors.
Risk factors
When modeling plan quality, various risk factors can
be used, including anatomy, treatment history, TPS pa-
rameters, physician’s experience, and institutional pro-
tocols. Here, we considered tumor dose requirements,
use of chemotherapy, surgery, and the patient’s anatomy
parametrized through 4 geometry- and 2 proximity-
based parameters. As described in Deasy et al,19 we
computed cross-sectional areas, volumes, spreads
(maximum distance in x, y, or z dimensions), and sur-
face areas of the PTV and OARs to capture the anatomic
geometry. We computed the nonnegative minimum
distance between the PTV and OARs, as well as the
distance between PTV and OAR centroids to capture the
proximity of structures.19 When the OAR overlaps the
PTV, the OAR-PTV overlap volume replaces the null
minimum distance. For tumor dose requirements, 6 PTV
DVH points D2, D20, D40, D60, D80, and D98 are used.
Therefore, a risk adjustment model for a plan quality
proxy consists of jZ1,.,18 risk factors: 6 PTV DVH
points, 4 PTV and 4 OAR geometric measures, 2
proximity measures, use of chemotherapy, and surgery.
When modeling the average monitor units, all OAR
geometry- and proximity-based risk factors were
employed in the original model.
Clinical data
A total of 69 head and neck cancer cases were used for
this study. Brainstem and spinal cord were identified as
the primary OARs to evaluate. Descriptive statistics about
the brainstem and spinal cord Dx are provided in Table 1.
Ipsilateral parotid was also identified as an organ of
importance (ipsilateral parotid descriptive statistics are
described in the supplemental material (Table E1 and E2)
available online at https://doi.org/10.1016/j.adro.2019.11.
006, accompanying the statistics describing average
monitor units). To parametrize tumor dose, geometry, and
proximity consistently, the largest PTV was considered
the primary target for each patient. The selection of the
largest PTV was deemed reasonable because PTVs were
treated sequentially for each patient; therefore, the largest
PTV encompassed all other PTVs in the patient’s treat-
ment course.
All patients underwent a computed tomography scan
(3-mm slice width) for treatment planning. All target and
OAR volumes were delineated and approved by the
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same physician to reduce variability in contouring and
minimize subjective preferences in planning criteria.20
Outlier detection was performed on the anatomic data
to identify inconsistencies in contouring, and resulted in
the redelineation of 3 plans. Treatment planning was
performed using Pinnacle3 (Philips) versions 6.2b to
9.10. Treatments were delivered with step-and-shoot
intensity modulation. Radiation doses were prescribed
for sequential delivery using a standard fractionation
scheme of 1.8 to 2.0 Gy or 1.5 Gy twice daily. The low-
risk target volume received 45 to 50 Gy while the
intermediate-to-high risk target volume received 56 to
66 Gy. The gross tumor volume typically received 70 to
72 Gy.
During the planning process, every attempt was made
to ensure that 100% of the prescribed dose covered at
least 95% of the target volume with a maximum dose
<110% of the prescribed dose. For OARs and normal
tissue, a combination of maximum dose and maximum
DVH objectives were used for optimization. When serial
OARs were in close proximity to treatment volumes,
priority was given to these OARs while still maintaining
adequate coverage for target volumes. A composite
DVH was developed from the sequential deliveries for
evaluation. The composite plan data were exported to a
computational environment for radiation therapy
research for data analysis via Digital Imaging and
Communications in Medicine (DICOM) file export from
Pinnacle3.19
Results
First, we provide the descriptive statistics of all risk
factors included in the modeling. Then, we focus on the
risk adjustment model and control charts for brainstem
and spinal cord D2 because this reflects the maximum
dose criteria commonly used to evaluate brainstem and
spinal cord doses for head and neck cases.21 The regres-
sion outputs, diagnostic plots, and control charts for D20,
D40, D60, D80, and D98 on the brainstem and spinal cord
accompanied the 6 DVH points for the ipsilateral parotid
and average monitor units in the supplemental material
(available online at https://doi.org/10.1016/j.adro.201
9.11.006).
Risk factors
The descriptive statistics on the PTV DVH points for
D2, D20, D40, D60, D80, and D98 for the 69 head and neck
cases are summarized in Table 2. One patient received a
low dose to the PTV, leading to a minimum D40Z8.2,
D60Z3.6, D80Z2.6, and D98Z0.1. This was unusual
compared with the remaining plans, with the second
lowest D40Z58.2, D60Z51.1, D80Z42.6, and D98Z1.6.
Statistics on the PTV, brainstem, and spinal cord ge-
ometries are summarized in Table 3. The mean cross-
sectional area, volume, and surface area for the PTV
were larger than the brainstem and spinal cord. However,
the spinal cord spread was observed to be larger than the
brainstem and the PTV.
Statistics on proximity measures, such as minimum
and centroid distances between the OARs and PTV are
summarized in Table 4. One patient had a PTV that
overlapped with the brainstem, leading to a no-minimum
distance between the structures. All remaining patients
had positive minimum distances between the PTV and
OARs. Furthermore, the average distance between the
brainstem and PTV centroids was larger than the average
distance between the spinal cord and PTV centroids.
Treatment history was incorporated by accounting for
concurrent chemotherapy (66 patients) and surgery (39
patients). These geometry-, proximity-, PTV dose-, and
treatment-based risk factors are incorporated into the risk
adjustment model.
Table 1 Descriptive statistics of brainstem and cord Dx
Brainstem Spinal cord
D2 D20 D40 D60 D80 D98 D2 D20 D40 D60 D80 D98
Minimum 5.50 2.70 1.70 1.30 0.90 0.70 25.10 6.90 4.70 3.90 0.30 0.10
Maximum 65.10 58.70 53.90 48.70 42.30 31.30 57.10 54.10 51.90 49.70 41.70 31.10
Mean 42.84 35.18 26.16 16.51 9.18 5.64 43.36 39.37 36.44 32.39 18.81 3.62
Median 44.70 37.10 26.90 14.70 5.70 3.90 42.90 39.50 36.70 32.10 19.50 1.70
Standard deviation 9.22 10.47 11.34 11.16 8.49 6.09 4.48 5.62 5.62 5.97 11.60 5.22
Abbreviations: Dx Z doses to x% brainstem volume.
Table 2 Descriptive statistics of PTV Dx
D2 D20 D40 D60 D80 D98
Minimum 61.5 37.0 8.2 3.6 2.6 0.1
Maximum 83.1 78.6 76.7 72.8 67.8 60.2
Mean 76.0 72.2 68.5 62.3 53.9 45.6
Median 76.4 73.3 70.1 62.8 54.5 47.2
Standard deviation 3.6 5.7 8.5 8.6 8.2 8.9
Abbreviations: Dx Z doses to x% brainstem volume.
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Risk adjustment model
The regression output from the risk adjustment model
for the brainstem and spinal cord D2 are reported in
Tables 5 and 6, respectively, with accompanying diag-
nostic plots shown in Figure 1. Although all 18 risk
factors were included in every OAR model, the final
model with the best fit risk factors using the Akaike in-
formation criterion is reported in the regression output in
Tables 5 and 6. The Akaike information criterion is most
commonly used for model selection, and measures the
relative quality of the regression model when risk factors
are removed iteratively to improve model quality.22
When modeling brainstem D2, model fit and signifi-
cance are reported by R2 Z 81.6% and P Z 2.2e-16,
respectively, as shown in Table 5. For spinal cord D2, R
2
Z 49.38% and P Z 7.47e-06 (Table 6). Both best fit
models produced significant results; however, the fit of
the brainstem model was substantially higher than the
spinal cord model.
For both risk adjustment models, the assumptions of
linearity, normality, and homoscedasticity appear valid.
The residual versus fitted values plot in Figure 1A shows
a random scattering of residuals around a mean of 0 and
within a horizontal band, demonstrating linearity in the
relationships between x and y, and homoscedasticity in
the residuals. The normal QeQ plot shows the residuals
lying approximately on the yZx line in Figure 1B,
demonstrating the normality of the residuals. Similar
observations are made in Figures 1C and D to reflect valid
assumptions for spinal cord D2
The residuals from the regression models are used as
the charting variable for the risk-adjusted control charts as
described in the following section.
Risk-adjusted control chart
Conventional individual control charts have been used
for the quality control of planning parameters in radiation
therapy. Therefore, we compared the results from the
proposed risk-adjusted control charts with those of the
conventional individual control charts for the brainstem
and spinal cord D2 Figure 2A demonstrates the conven-
tional chart plotting brainstem D2, with an UCLZ63.5Gy
and LCLZ22.2 Gy. Patient 4 was identified as out OC
based on a high D2Z65.1 Gy compared with the
remaining plans. Conversely, patients 42, 51, and 52 were
identified as OC based on their low brainstem
D2Z20.3Gy, 6.1Gy, and 5.5Gy, respectively.
Figure 2B displays the conventional chart for spinal
cord D2, with UCLZ54.2Gy and LCLZ32.5Gy. Patient
1 was identified as OC based on their spinal cord
D2Z57.1Gy that exceeds the UCL. Patient 43 was iden-
tified as OC based on their spinal cord D2Z25.1Gy that is
unusually low compared with the remaining patients.
For our proposed method, Figure 2C depicts the risk-
adjusted individual chart plotting the residuals from the
brainstem D2 model, with UCLZ11.6 Gy and
LCLZ11.6Gy. Unlike the conventional chart, no pa-
tients had an OC brainstem D2 after accounting for the
best fit risk factors. Figure 2D illustrates the risk-adjusted
control chart for spinal cord D2 with UCLZ9.0 Gy and
Table 3 Minimum, mean, median, maximum, and standard deviation of the PTV, brainstem, and spinal cord geometries
Structure Cross-sectional area (cm2) Volume (cm3)
Min Mean Median Max SD Min Mean Median Max SD
PTV 27.0 68.7 67.0 145.1 20.5 289.9 1317.7 1254.5 2451.5 448.0
Brainstem 1.7 4.2 4.1 10.5 1.5 9.4 27.4 26.4 47.3 6.7
Spinal cord 0.5 1.0 1.0 1.8 0.3 10.8 21.3 21.0 34.4 4.8
Structure Spread (cm) Surface area (cm2)
Min Mean Median Max SD Min Mean Median Max SD
PTV 10.2 20.5 20.7 28.6 3.3 239.2 969.1 974.4 1477.0 229.1
Brainstem 3.3 5.8 6.0 7.5 0.8 24.3 57.4 56.7 84.3 10.1
Spinal Cord 14.4 20.1 20.1 24.3 2.1 65.6 126.0 126.8 186.8 24.5
Abbreviations: max Z maximum; min Z minimum; PTV Z planning target volume; SD Z standard deviation.
Table 4 Descriptive statistics of proximity between PTV
and organs at risk















Minimum 0.0 6.5 0.5 3.9
Maximum 2.6 12.5 1.7 14.0
Mean 0.8 10.1 0.9 6.0
Median 0.7 10.2 0.9 5.8
Standard
deviation
0.4 1.2 0.2 1.4
Abbreviation: PTV Z planning target volume.
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LCLZ9.0 Gy, where only patient 19 was identified as
an unusual plan with a low spinal cord D2Z36.9 Gy.
For the remaining brainstem DX, the risk-adjusted
control chart identified patients 4 and 58 with unusually
high D80 and D98, and patient 61 was identified with
unusually low D20 (Fig E4; available online at https://doi.
org/10.1016/j.adro.2019.11.006). For the remaining spi-
nal cord Dx, the plans for patients 1 and 3 produced an
unusually high spinal cord D98 (Fig E5; available online
at https://doi.org/10.1016/j.adro.2019.11.006).
For the ipsilateral parotid, patient 1 was OC owing to a
low D2 and a low D20, patient 51 was OC due to a low
D40, and patients 52 and 54 were OC due to a low D60
(Fig E6; available online at https://doi.org/10.1016/j.
adro.2019.11.006). When evaluating average monitor
units, 2 plans were identified as OC in the conventional
chart, with patients 31 and 61 having an unusually high
number of average monitor units. Patient 31 remained OC
in the risk-adjusted chart, and patient 61 was adjusted to
be in control (Fig E7; available online at https://doi.org/1
0.1016/j.adro.2019.11.006).
Discussion
Many patients were identified as OC in the conven-
tional charts across the DVH points for all 3 OARs and
average monitor units. This was expected owing to the
large variability in the DVHs and monitor units across
patients. The risk-adjusted control chart typically reduced
the number of OC plans by attributing some of the vari-
ability between patients to their respective risk factors.
For example, compared with the entire patient set, the
minimum distances between the PTVs and brainstems for
patients 51 and 52 were >3.4 SD above the mean. This
contributes to the unusually low brainstem D2. Similarly,
Table 6 Regression output for modeling spinal cord D2
Coefficients Estimate Standard error t statistic P-value
Intercept 52.9373 11.0490 4.791 1.19E-05
PTV cross-sectional area 0.0697 0.0311 2.241 0.0289
PTV 0.0073 0.0023 3.238 0.00199
PTV spread 0.4188 0.2779 1.507 0.13728
PTV surface area 0.0034 0.0021 1.638 0.10689
Minimum distance cord e PTV 14.2842 2.3202 6.157 7.51E-08
Cord volume 0.1930 0.0959 2.013 0.04881
PTV D2 0.3003 0.1445 2.078 0.04213
PTV D40 0.4475 0.1873 2.389 0.02019
PTV D60 0.8087 0.2585 3.128 0.00275
PTV D80 0.5125 0.1526 3.358 0.00139
Multiple R2 49.38% f statistic 5.657
Adjusted R2 40.65% P-value 7.47e-06
Residual standard error 3.452
Abbreviations: Dx Z doses to x% brainstem volume; PTV Z planning target volume.
Table 5 Regression output for modeling brainstem D2
Coefficients Estimate Standard error t statistic P-value
Intercept 74.7313 8.1357 9.186 6.56E-13
PTV cross-sectional area 0.1671 0.0412 4.057 0.00015
PTV 0.0119 0.0024 4.953 6.66E-06
PTV surface area 0.0040 0.0026 1.556 0.125181
Minimum distance brainstem e PTV 13.4698 1.5823 8.513 8.52E-12
Centroid distance brainstem e PTV 2.9535 0.7141 4.136 0.000115
Brainstem volume 0.2113 0.1070 1.975 0.052981
Brainstem spread 2.4817 0.8362 2.968 0.004352
PTV D40 0.3121 0.2250 1.387 0.170833
PTV D60 0.8202 0.3271 2.507 0.014983
PTV D80 0.5501 0.1853 2.969 0.004341
Multiple R2 81.58% f statistic 25.69
Adjusted R2 78.40% P-value 2.2e-16
Residual standard error 4.284
Abbreviations: Dx Z doses to x% brainstem volume; PTV Z planning target volume.
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for patient 42, the minimum distance was >2.8 SD above
the mean. For patient 4, the minimum distance was
0 owing to volume overlap between the brainstem and
PTV. Because this minimum distance is almost 2 SD
below the mean, the close proximity to the PTV
contributed to the high brainstem D2.
In the case of patient 1, the minimum distance was
>1.7 SD below the mean. The close proximity to the PTV
contributed to a high spinal cord D2. Conversely, for
patient 43, the minimum distance was >3.7 SD above the
mean, which contributed to the low spinal cord D2. Pa-
tient 19’s spinal cord spinal cord D2 remained in control
in the conventional chart, but the risk-adjusted chart sig-
nals OC after accounting for the risk factors. For this
patient, the larger PTV (1.7 SD above the mean) and
higher PTV dose (above average PTV D60 and D80) was
used to adjust the spinal cord D2 to be unusually low in
the risk-adjusted chart. Similar observations were made
from other best fit risk factor variables that directly led to
the adjustments between the conventional and risk-
adjusted control charts for the remaining Dx on the
brainstem, spinal cord, ipsilateral parotid, and average
monitor units.
At clinics, the risk-adjusted control chart can poten-
tially improve the workflow and quality of radiation
treatments. For example, the proposed chart can evaluate
an optimized plan to be of high quality (in control) after
accounting for risk factors, even if the OAR planning
criteria are not met. In other words, the control chart can
identify plans where improving the OAR planning criteria
is only possible at the cost of worsening other risk factors,
such as tumor dose distribution. Thus, the proposed chart
can help reduce planning time and improve quality for
such cases by identifying truly high-quality plans without
having to iteratively modify planning criteria.
Furthermore, the typical treatment planning approval
process in a clinical setting involves comparing maximum
dose and DVH criteria for the OARs to established
guidelines, such as Quantitative Analyses of Normal
Tissue Effects in the Clinic.23 These guidelines are
Figure 1 Residual diagnostic plots for (a, b) brainstem, and (c, d) spinal cord doses to 2% brainstem volume. Residual versus fitted
plot shows linear relationship in variables and homoscedasticity in residuals and normal QeQ plot shows normality of residuals.
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directly related to risk of toxicity. Of note, a proxy for
plan quality, as discussed herein, is not necessarily
correlated to toxicity probability. The proposed quality
control methodology aims to identify unusual plans based
on historical patient data and is independent of meeting
toxicity constraints. For patients who need to be treated
for secondary cancers or re-treated for a primary cancer,
the reduction of low doses that already meet the toxicity
guidelines will be of value. An unusually low OAR dose
is of less concern, but an OAR dose that exceeds the UCL
does increase the potential for adverse effects and can be a
cause for an additional review of the plan.
The proposed chart can also be used to monitor future
patient’s plans rather seamlessly. Given an existing
database of already treated patient plans, the risk adjust-
ment regression Equation 1 can be used to model any plan
quality proxy, such as an OAR Dx. Next, residuals ob-
tained from the adjustment model can be used to establish
control limits using Equations 2 and 3. Similarly, for a
new patient, Equation 1 can be used to model for the same
quality proxy, and Equations 2 and 3 can be used to
compute the residual. Finally, the residual is plotted on
the risk-adjusted control chart, reflecting the quality of the
new patient’s treatment plan. If the residual is within the
limits, the plan is acceptable. However, if the residual is
OC, further review is needed. Another appealing feature
of a control chart is the ability to capture the trend of the
planning parameter over time because patients are plotted
in chronological order. Not only can trends in planning
criteria be visually observed, there are additional order-
based quality evaluation criteria that accompany the
control limits, which can be employed in the risk-adjusted
control chart setting (out of the scope of this work). These
include 8 consecutive points above or below the center-
line, 4 of 5 consecutive points beyond 1 SD, and 2 of 3
consecutive points beyond 2 SD that signal a plan to be
unusual. These additional measures of quality over time
do not exist and cannot be accomplished within the cur-
rent KPB framework.
In addition to the anatomic parameters discussed
herein, other parameterizations, such as portions of OAR
outside the primary target fields and tumor site, can be
easily considered.6,11 Beam information, such as beam
angles and field arrangements, can also be included.
However, given that there are many such planning pa-
rameters, external factors, and anatomic parametrizations
that could be included in this framework, an exhaustive
model considering all risk factors is outside of the scope
of this proof of concept.
Unlike control charts that monitor mean, range, or SD
that use large subgroup sizes and rely on the central limit
theorem, individual charts include a subgroup size of one
and thus are sensitive to nonnormal distributions.18
Nonparametric control charts have been studied in the
past, and change-point methods have been proposed to
detect shifts in observations over a period in time.24,25
Figure 2 (a) Conventional and (b) risk-adjusted control charts for brainstem doses to 2% brainstem volume and (c) conventional and
(d) risk-adjusted control charts for spinal cord doses to 2% brainstem volume.
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Although effective to detect prolonged shifts, these ap-
proaches are limited in identifying sporadic OC points
and do not account for risk factors that may affect the
process quality. As a result, developing nonparametric
risk-adjusted control charts serve as an extension of this
work. In the same context, extreme outliers can affect the
width of the control limits when SD is used to capture the
variability in the data. In such a case, a more robust es-
timate of variability, such as median absolute deviation,
can be used to compute the control limits.26 Furthermore,
standardizing the contouring of OARs can reduce outliers,
leading to more acceptable control limits. Moreover, the
quality control of OAR DVH can also be extended to a
multivariate setting or profile monitoring, where multiple
OAR Dx or the entire OAR DVH profile can be param-
etrized for risk adjustment. Capability indices have been
used by Breen et al27 and Sanghangthum et al28 in radi-
ation therapy to demonstrate that their dosimetry process
was within acceptable user specification limits. Extending
the indices to the risk-adjusted setting will be considered
in future work.
Ideally, clinics should have the ability to readily apply
the control chart framework to their patient data without
tediously curating and formatting the data, as was
required for this proof of concept. For example, DVH
Analytics is an open-source DICOM radiation therapy
database software that can read large batches of DICOM
files and compute various anatomic and dose values, store
them in an SQL database, and provide a graphical user
interface to explore the data.29
Furthermore, as the treatment planning process con-
tinues to evolve toward fully automated planning, the
quality assurance of planning criteria becomes even more
important because optimization algorithms often produce
locally optimum solutions in radiation therapy.30 The
proposed control chart methodology can employ large
databases of existing plans to help identify locally optimal
plans that could be improved through reoptimization of
planning parameters.
Conclusions
A risk-adjusted control chart was developed to detect
unusual planning criteria after accounting for patient- and
treatment-specific risk factors, allowing for multiple plan
comparisons on a large scale. When evaluating 69 head
and neck cases, the risk-adjusted control charts were
robust to the interpatient variations in anatomy, tumor
dose prescription, use of chemotherapy, and surgery.
Furthermore, the charts reduced the number of unusual
plans compared with conventional control charts.
Detecting unusually high OAR doses in risk-adjusted
charts provides the clinician with a chance to review the
treatment plan within the context of historical patient data
and probe for possible improvements to reduce the po-
tential for adverse effects.
Supplementary data
Supplementary material for this article can be found at
https://doi.org/10.1016/j.adro.2019.11.006.
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